APA (7th ed.) Citation

SH, S., HY, K., HS, Y., WJ, P., DR, A., NJ, P., . . . JW, P. (2020). A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes. International journal of molecular sciences, 21(21), . https://doi.org/10.3390/ijms21218371

Chicago Style (17th ed.) Citation

SH, Shin, Kim HY, Yoon HS, Park WJ, Adams DR, Pyne NJ, Pyne S, and Park JW. "A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes." International Journal of Molecular Sciences 21, no. 21 (2020). https://doi.org/10.3390/ijms21218371.

MLA (9th ed.) Citation

SH, Shin, et al. "A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes." International Journal of Molecular Sciences, vol. 21, no. 21, 2020, https://doi.org/10.3390/ijms21218371.